Evaluation of PHR160 Spray Effect on Improvement of Lung Function, Asthma Severity and Exacerbation in Severe Asthmatic Patients

Q3 Medicine Acta medica Iranica Pub Date : 2024-07-17 DOI:10.18502/acta.v61i11.16080
Mehrdad Dargahi-Malamir, S. Borsi, Zahra Mehraban, Fatemeh Kianizadeh, Hoda Mohsenikia
{"title":"Evaluation of PHR160 Spray Effect on Improvement of Lung Function, Asthma Severity and Exacerbation in Severe Asthmatic Patients","authors":"Mehrdad Dargahi-Malamir, S. Borsi, Zahra Mehraban, Fatemeh Kianizadeh, Hoda Mohsenikia","doi":"10.18502/acta.v61i11.16080","DOIUrl":null,"url":null,"abstract":"Pinen Hydronoplacton Ribonucleic acid (PHR160) medicine contains compounds that can be useful in the recovery of respiratory patients. The aim of this study was to determine the effect of PHR spray on improving lung function, severity and asthma attacks in patients with severe asthma. This study is a pioneering interventional study (pilot study) conducted during the years 2021-2022 on patients with severe asthma resistant to treatment who referred to the lung clinic of Imam Khomeini, Golestan Hospitals and the private practice of lung specialists of this academic center. The study includes two groups of patients with asthma, both groups were given the usual treatment according to the stage of the disease, in addition, the intervention group was given two puffs of PHR spray every eight hours, and the control group was given a placebo spray with the same dose. Before and after the intervention, GSK 2002 questionnaire, six-minute walk distance (6MWD) and spirometry tests were completed. Among of 60 patients, 27 (45%) were male. The mean age of the patients was 44.33±6.94 years. Based on findings, the forced vital capacity (FVC) and forced expiratory flow between 25% and 75% (FEF 25-75%) were significantly better in the intervention group than the control group (P<0.001 and P=0.019, respectively), but there was a statistically remarkable difference between the two groups in terms of forced expiratory volume (FEV1) and FEV1/FVC (P=0.505, P=0.575, respectively). In addition, the GSK questionnaire score in the intervention group was higher than the control group (P<0.001), however there is no significant difference between the two intervention groups in terms of the 6MWD test and the number of exacerbation (P=0.114 and P=0.09, respectively). It is generally concluded that PHR160 spray can lead to improvement of spirometry parameters and severity of disease in severe asthma patients by affecting small airways.","PeriodicalId":6946,"journal":{"name":"Acta medica Iranica","volume":" 8","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta medica Iranica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18502/acta.v61i11.16080","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Pinen Hydronoplacton Ribonucleic acid (PHR160) medicine contains compounds that can be useful in the recovery of respiratory patients. The aim of this study was to determine the effect of PHR spray on improving lung function, severity and asthma attacks in patients with severe asthma. This study is a pioneering interventional study (pilot study) conducted during the years 2021-2022 on patients with severe asthma resistant to treatment who referred to the lung clinic of Imam Khomeini, Golestan Hospitals and the private practice of lung specialists of this academic center. The study includes two groups of patients with asthma, both groups were given the usual treatment according to the stage of the disease, in addition, the intervention group was given two puffs of PHR spray every eight hours, and the control group was given a placebo spray with the same dose. Before and after the intervention, GSK 2002 questionnaire, six-minute walk distance (6MWD) and spirometry tests were completed. Among of 60 patients, 27 (45%) were male. The mean age of the patients was 44.33±6.94 years. Based on findings, the forced vital capacity (FVC) and forced expiratory flow between 25% and 75% (FEF 25-75%) were significantly better in the intervention group than the control group (P<0.001 and P=0.019, respectively), but there was a statistically remarkable difference between the two groups in terms of forced expiratory volume (FEV1) and FEV1/FVC (P=0.505, P=0.575, respectively). In addition, the GSK questionnaire score in the intervention group was higher than the control group (P<0.001), however there is no significant difference between the two intervention groups in terms of the 6MWD test and the number of exacerbation (P=0.114 and P=0.09, respectively). It is generally concluded that PHR160 spray can lead to improvement of spirometry parameters and severity of disease in severe asthma patients by affecting small airways.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
评估 PHR160 喷雾剂对改善重度哮喘患者肺功能、哮喘严重程度和病情恶化的影响
Pinen Hydronoplacton Ribonucleic acid(PHR160)药物含有对呼吸道患者的康复有用的化合物。本研究旨在确定 PHR 喷雾剂对改善严重哮喘患者的肺功能、严重程度和哮喘发作的效果。本研究是一项开创性的干预研究(试点研究),于 2021-2022 年期间进行,对象是转诊至伊玛目霍梅尼医院、戈勒斯坦医院肺部诊所和该学术中心肺部专家私人诊所的治疗无效的重症哮喘患者。该研究包括两组哮喘患者,两组患者均根据疾病阶段接受常规治疗,此外,干预组每八小时喷洒两次 PHR 喷雾剂,而对照组则喷洒相同剂量的安慰剂。干预前后完成了 GSK 2002 调查问卷、六分钟步行距离(6MWD)和肺活量测试。在 60 名患者中,27 人(45%)为男性。患者的平均年龄为(44.33±6.94)岁。根据研究结果,干预组的用力肺活量(FVC)和25%-75%之间的用力呼气流量(FEF 25-75%)明显优于对照组(分别为P<0.001和P=0.019),但在用力呼气容积(FEV1)和FEV1/FVC方面,两组间存在显著统计学差异(分别为P=0.505和P=0.575)。此外,干预组的 GSK 问卷得分高于对照组(P<0.001),但在 6MWD 测试和病情加重次数方面,两组间无显著差异(分别为 P=0.114 和 P=0.09)。综上所述,PHR160 喷雾剂可通过影响小气道改善严重哮喘患者的肺活量指标和病情严重程度。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Acta medica Iranica
Acta medica Iranica Medicine-Medicine (all)
CiteScore
0.70
自引率
0.00%
发文量
83
审稿时长
18 weeks
期刊介绍: ACTA MEDICA IRANICA (p. ISSN 0044-6025; e. ISSN: 1735-9694) is the official journal of the Faculty of Medicine, Tehran University of Medical Sciences. The journal is the oldest scientific medical journal of the country, which has been published from 1960 onward in English language. Although it had been published quarterly in the past, the journal has been published bimonthly (6 issues per year) from the year 2004. Acta Medica Iranica it is an international journal with multidisciplinary scope which publishes original research papers, review articles, case reports, and letters to the editor from all over the world. The journal has a wide scope and allows scientists, clinicians, and academic members to publish their original works in this field.
期刊最新文献
Effect of Gestational Hypertension on Neonatal Hemoglobin Level A Review on Novel Methods of Pharmacology Teaching Concerning Iranian Academic Context Transcatheter Closure of a Huge Congenital Coronary-Cameral Fistula With Amplatzer Occluder Erythrocyte Antioxidants and Hexokinase Activity Alterations in CCl4-Induced Cirrhotic Rats Through Naltrexone Treatment Upright Versus Recumbent Position in the Second Stage of Labor for Women With Epidural Analgesia: A Randomized Clinical Trial
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1